ARC Hub for Therapeutics
Summary
The ARC Hub for Therapeutics is committed to driving national and regional growth and innovation in Biopharma and Life Sciences. The Hub is designed to unite the Irish biopharma ecosystem – venture capitalists, indigenous companies, state agencies and a network of promoters and advisors – resulting in a broad alliance capable of identifying, guiding and facilitating academic projects to commercial success. The Hub strives to create the next generation of entrepreneurs through entrepreneurial training, engagement with external experts, and first-hand experience of taking their therapeutic innovations to market.
Research Areas
The ARC Hub for Therapeutics encompasses a broad spectrum of therapeutic areas, with strengths in oncology and immunology. Its research emphasises translational research in small molecule therapies, biological treatments, biomaterials for Advanced Therapy Medicinal Product (ATMP) applications, and biomarkers with therapeutic utility.
Research Programme
The ARC Hub for Therapeutics accelerates the transition of outstanding discoveries in Irish biomedical research to commercial success.
Current translational projects include:
- ALPACA BIO: Antimicrobial Peptides for Vaginal Candidiasis
- Preparing Anti-Cancer RNA Therapeutics for Commercialisation and Clinical Translation
- Inhalable formulations for the treatment of lung infections
- Commercial development of prophylactic vaccines against antimicrobial resistant bacterial priority pathogens
- Gene therapy for Drug-Refractory Epilepsy and Other CNS diseases
- Novel, Selective pro-Haemostatic Therapies for Enhanced Treatment of Bleeding Disorders.
Academic Partners
- TCD
- UCD
- RCSI
- DCU
- UoG
- UL
- UCC
- MU
- NIBRT
Interested in being involved with the Hub?
The ARC Hub for Therapeutics is always looking for motivated researchers and industry partners. To find out more, contact:
Hub Director: Prof. Vincent Kelly, kellyvp@tcd.ie , Tel: +353 1896 3507